7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
RecruitingNCT05697159
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients. The investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate. The second is related to peripheral inflammation, specifically joint synovitis, blood cytokines/chemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.
Study details
- Official title
- Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Sickness Behavior
- Inflammatory Disease
- Autoimmune
- Pain, Chronic
- Sponsor
- NHS Greater Glasgow and Clyde
- Collaborators
- Lakefront Biotherapeutics NV
- Start date
- 2023-08-22
- Primary completion
- 2025-07-31
- Sex
- All
- Age range
- from 18 Years to 74 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are: * Adults ≥18 years \< 75 years. * Right-handed (to reduce neuroimaging heterogeneity). Exclusion Criteria: * Inability to provide written informed consent. * Severe physical impairment (e.g. blindness, deafness, paraplegia). * Pregnant or breast feeding. * Severe claustrophobia precluding MRI. * Contraindications to MRI. * Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury. * Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05697159